For patients with acute myocardial infarction, goal glucose levels of 140-180 mg/dL using an intravenous insulin infusion are recommended, alongside standard non-glycemic therapies.
This review highlights that while strict glycemic control with glucose-insulin-potassium has not shown outcome efficacy and hypoglycemia poses significant risks, targeting glucose levels of 140-180 mg/dL with IV insulin and adhering to standard non-glycemic AMI therapies is the recommended approach for patients with diabetes and AMI.
Acute myocardial infarction (AMI) is common in patients with diabetes. Reasons for this are multifactorial, but all relate to a variety of maladaptive responses to acute hyperglycemia. Persistent hyperglycemia is associated with worse left ventricular function and higher mortality during AMI, but intervention data are far from clear. Although there is a theoretical basis for the use of glucose-insulin-potassium infusion during AMI, lack of outcome efficacy (and inability to reach glycemic targets) in recent randomized trials has resulted in little enthusiasm for this strategy. Based on the increasing understanding of the dangers of hypoglycemia, while at the same time appreciating the role of hyperglycemia in AMI patients, goal glucose levels of 140-180 mg/dL using an intravenous insulin infusion while not eating seem reasonable for most patients and hospital systems. Non-glycemic therapy for patients with diabetes and AMI has benefited from more conclusive data, as this population has greater morbidity and mortality than those without diabetes. For ST-elevation myocardial infarction (STEMI), reperfusion therapy with primary percutaneous coronary intervention or fibrinolysis, antithrombotic therapy to prevent acute stent thrombosis following percutaneous coronary intervention or rethrombosis following thrombolysis, and initiation of β-blocker therapy are the current standard of care. Emergency coronary artery bypass graft surgery is reserved for the most critically ill. For those with non-STEMI, initial reperfusion therapy or fibrinolysis is not routinely indicated. Overall, there have been dramatic advances for the treatment of people with AMI and diabetes. The use of continuous glucose monitoring in this population may allow better ability to safely reach glycemic targets, which it is hoped will improve glycemic control.
Hirsch et al. (2012) conducted a review in Acute myocardial infarction and diabetes. Glycemic and non-glycemic management was evaluated. For patients with acute myocardial infarction, goal glucose levels of 140-180 mg/dL using an intravenous insulin infusion are recommended, alongside standard non-glycemic therapies.